RESUMEN
Inflammatory bowel disease characteristically affects young adults in their reproductive ages. Thus the medication used for the treatment of active disease should not compromise fertility and, also, should not have teratogenic effect on baby. A lot of data are available about effects of steroids, antibiotics, and mesalazine but no data are available about safety and efficacy of granulocyte-monocyte-apheresis (GMA) during pregnancy. In this case report, the 37 year-old pregnant woman with chronically active and steroid dependent ulcerative colitis (UC), at risk of abortion, refused more aggressive pharmacological therapeutic options and gave the informed consent to GMA. To minimize symptoms and the risk of severe clinical relapse, a maintenance GMA treatment was performed throughout pregnancy. The course of pregnancy was uneventful with no side effects; the mother and the baby were all healthy and well at the delivery.
Asunto(s)
Colitis Ulcerosa/complicaciones , Colitis Ulcerosa/terapia , Leucaféresis/métodos , Complicaciones del Embarazo/terapia , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , Colitis Ulcerosa/sangre , Terapia Combinada , Femenino , Granulocitos , Humanos , Recién Nacido , Mesalamina/uso terapéutico , Monocitos , Embarazo , Complicaciones del Embarazo/sangre , Complicaciones del Embarazo/inmunología , Resultado del EmbarazoRESUMEN
The fundamental role of antibodies in the development of acute graft rejection has been established recently. Antibody-mediated acute rejection may develop at any time during the post-transplant period. Several therapeutic approaches have been proposed in the last decades. However, there is no standardized therapy. The aim of this study is to report the Sapienza University experience of combined plasma treatment and high-dose intravenous immunoglobulin ± extracorporeal photopheresis. From January 2006 to September 2009, 6 patients were treated at Sapienza University. In 5 cases (83%) complete regression of the acute rejection was observed, followed by stable renal function (median creatinine value at 1-year follow-up: 1.5 mg/dL). No adverse events were reported. Our approach seems to give good results in terms of graft survival and procedure safety. Further studies on a larger number of patients will be needed to confirm the validity of these findings. Moreover, comparison between our protocol and other treatments is necessary.
Asunto(s)
Rechazo de Injerto/terapia , Supervivencia de Injerto , Inmunoglobulinas Intravenosas/uso terapéutico , Trasplante de Riñón , Fotoféresis , Plasmaféresis , Enfermedad Aguda , Adulto , Terapia Combinada/métodos , Femenino , Estudios de Seguimiento , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Humanos , Trasplante de Riñón/inmunología , Masculino , Persona de Mediana Edad , Plasmaféresis/métodos , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
AIM: To identify factors predicting the clinical response of ulcerative colitis patients to granulocyte-monocyte apheresis (GMA). METHODS: Sixty-nine ulcerative colitis patients (39 F, 30 M) dependent upon/refractory to steroids were treated with GMA. Steroid dependency, clinical activity index (CAI), C reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), values at baseline, use of immunosuppressant, duration of disease, and age and extent of disease were considered for statistical analysis as predictive factors of clinical response. Univariate and multivariate logistic regression models were used. RESULTS: In the univariate analysis, CAI (P = 0.039) and ESR (P = 0.017) levels at baseline were singled out as predictive of clinical remission. In the multivariate analysis steroid dependency [Odds ratio (OR) = 0.390, 95% Confidence interval (CI): 0.176-0.865, Wald 5.361, P = 0.0160] and low CAI levels at baseline (4 < CAI < 7) (OR = 0.770, 95% CI: 0.425-1.394, Wald 3.747, P = 0.028) proved to be effective as factors predicting clinical response. CONCLUSION: GMA may be a valid therapeutic option for steroid-dependent ulcerative colitis patients with mild-moderate disease and its clinical efficacy seems to persist for 12 mo.
Asunto(s)
Eliminación de Componentes Sanguíneos , Colitis Ulcerosa/terapia , Resistencia a Medicamentos , Granulocitos/metabolismo , Monocitos/metabolismo , Esteroides/uso terapéutico , Adulto , Anciano , Femenino , Granulocitos/citología , Humanos , Masculino , Persona de Mediana Edad , Monocitos/citología , Resultado del TratamientoAsunto(s)
Adenocarcinoma Mucinoso/etiología , Enfermedad de Crohn/complicaciones , Neoplasias del Recto/etiología , Adenocarcinoma Mucinoso/patología , Adenocarcinoma Mucinoso/terapia , Neoplasias del Ano/etiología , Neoplasias del Ano/patología , Neoplasias del Ano/terapia , Humanos , Masculino , Persona de Mediana Edad , Fístula Rectal/complicaciones , Neoplasias del Recto/patología , Neoplasias del Recto/terapia , Resultado del TratamientoRESUMEN
Therapeutic apheresis, a novel approach for immunodisorders, has been used in the last decade for the treatment of ulcerative colitis with promising result, and represents an alternative to conventional pharmacological therapy. Selective apheresis is aimed at reducing the number of circulating lymphocytes, interfering with recruitment and activation of mucosal granulocytes and macrophages, reducing cytokine and chemokine production which are thought to contribute to induction and perpetuation of inflammation. The article briefly reports indications, treatment schedule and clinical results of leukocytapheresis in ulcerative colitis. Available data for the two selective adsorption devices so far approved for clinical use (granulocyte-monocyte apheresis- Adacolumn- and leukocytapheresis-Cellsorba) are partially conflicting, and the number of controlled studies too small to draw definitive conclusions. Nonetheless apheresis definitely appears to be an effective non-conventional tool for the treatment of steroid refractory and steroid dependent UC patients with moderately active disease. The excellent safety profile of the procedure makes this approach attractive, both in adult and in pediatric patients, more so in those refractory to conventional drug therapy, who are presently treated with immunosuppressive and biological therapies.